FFM
CBIO

Fairmount Funds Management’s Crescent Biopharma CBIO Stock Holding History

Fairmount Funds Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.5M Hold
2,747,866
– – 3.27% 9
2026
Q1 		$50.5M Hold
2,747,866
– – 3.65% 9
2025
Q4 		$32.6M Buy
2,747,866
+1,360,000
+98% +$17.3M 2.48% 12
2025
Q3 		$16.5M Hold
1,387,866
– – 1.48% 16
2025
Q2 		$22.4M Buy
+1,387,866
New +$29.4M 2.9% 13

Other funds holding CBIO

LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
NCM
NEXTBio Capital Management Menlo Park, California $217M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fairmount Funds Management's CBIO Position: Q2 2026 in Review

Fairmount Funds Management held its Crescent Biopharma (CBIO) position steady in Q2 2026 at 2,747,866 shares worth $49.5M. The position accounts for 3.27% of the portfolio, ranked #9.

Fairmount Funds Management first reported a position in CBIO in Q2 2025 and has held it in 5 quarters since. The position peaked at $50.5M in Q1 2026. 70 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Fairmount Funds Management held 2,747,866 shares of Crescent Biopharma worth $49.5M as of Q2 2026.
  • Fairmount Funds Management left its Crescent Biopharma share count unchanged in Q2 2026.
  • Crescent Biopharma made up 3.27% of Fairmount Funds Management's portfolio in Q2 2026, its #9 holding.
  • Fairmount Funds Management first reported a position in Crescent Biopharma in Q2 2025 and has held it in 5 quarters since.
  • Fairmount Funds Management's Crescent Biopharma position peaked at $50.5M in Q1 2026.
  • 70 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Fairmount Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.